Prolotherapy fails for some people because of medication interference, inaccurate needle placement, inconsistent treatment protocols, or simply because the clinical evidence behind it remains mixed. When researchers have tried to determine whether prolotherapy reliably works, the results have been inconclusive for several conditions, and individual treatment failures often trace back to specific, identifiable factors that prevented the intended healing response.
What Prolotherapy Is Supposed to Do
Prolotherapy involves injecting an irritant solution, most commonly concentrated dextrose (sugar water), into damaged ligaments, tendons, or joints. The idea is that the irritant triggers a localized inflammatory response, which then stimulates the body’s natural tissue repair process. Dextrose concentrations above 10% are considered to work through this inflammatory mechanism, while lower concentrations are not. Most practitioners use concentrations between 12.5% and 25%.
The treatment typically requires multiple sessions spaced weeks apart. If that inflammatory cascade doesn’t happen as intended, or if something interrupts the healing process afterward, the treatment produces little to no benefit.
The Clinical Evidence Is Inconclusive
The most rigorous look at prolotherapy for chronic low back pain, a Cochrane systematic review, found that prolotherapy injections alone were no more effective than control injections in three randomized controlled trials covering 206 participants. Two other trials involving 160 participants did find benefit, but only when prolotherapy was combined with spinal manipulation, exercise, and other therapies. The reviewers couldn’t determine whether the prolotherapy itself was responsible for the improvement or whether the co-interventions did the heavy lifting.
A recurring problem across prolotherapy research is that treatment protocols vary dramatically from study to study. Different practitioners use different solutions, concentrations, injection sites, and session frequencies. This makes it nearly impossible to pool results into a single statistical analysis. As the Cochrane reviewers noted, clinical heterogeneity among studies prevented meaningful meta-analysis. In practical terms, this means there’s no standardized version of prolotherapy that’s been proven to work consistently.
Some individual studies do show positive results. One small trial of 20 people with elbow pain found a 90% reduction in resting pain for the prolotherapy group compared to 22% in controls. The largest low back pain study showed 26 to 44% reductions in pain and 30 to 44% reductions in disability at 12 months, but those improvements were not statistically significant compared to the control group. That’s an important distinction: patients felt better, but so did people who received a placebo injection.
Medications That Block the Healing Response
One of the most common and overlooked reasons prolotherapy fails is medication interference. The entire treatment depends on triggering inflammation, so anything that suppresses inflammation can undermine it. NSAIDs like ibuprofen and naproxen are the most obvious culprits. Practitioners typically instruct patients to avoid all NSAIDs for at least 24 hours before each injection and for the duration of the treatment course. But many patients take these drugs habitually for chronic pain and may not fully stop.
Corticosteroids pose a similar problem. Regular use of oral or injected corticosteroids counteracts the inflammatory processes that prolotherapy relies on. Long-term narcotic use also suppresses immune response, which can dampen the body’s ability to mount the tissue repair cascade. If you’re on any of these medications during a prolotherapy course, the treatment is working against your own pharmacology.
Inaccurate Needle Placement
Prolotherapy only works if the solution reaches the right tissue. Many practitioners perform injections based on anatomical landmarks and feel alone, without imaging guidance. The accuracy gap between these approaches is significant.
For shoulder joint injections, blind technique averages 79% accuracy compared to 95% with image guidance. For hip joints, the difference is even more dramatic: 72% accuracy for blind injections versus 100% for ultrasound-guided ones. One study on wrist joint injections found that sites marked by experienced rheumatologists were, on average, nearly a centimeter away from the actual joint space identified by imaging. Across all joints studied, image-guided injections are consistently more accurate than palpation-guided ones.
If the solution lands in surrounding tissue rather than the damaged structure, you get an inflammatory response in the wrong location. The target ligament or tendon never receives the intended stimulus, and the treatment appears to have failed when it was really a placement problem.
Solution Type and Concentration Matter
Not all prolotherapy solutions are the same. While dextrose is the most common agent, practitioners also use combinations involving other substances like phenol, glycerin, or polidocanol. The concentration of dextrose varies widely in practice, from 12.5% to 25%, and the specific mix of additional ingredients (typically a local anesthetic like lidocaine) differs between providers.
Research hasn’t established that one specific concentration works better than another for a given joint or condition. This means your outcome partly depends on your practitioner’s preferences and experience. A concentration that’s too low may not trigger sufficient inflammation. The lack of standardization across the field means two patients receiving “prolotherapy” may be getting meaningfully different treatments.
Lifestyle Factors That Impair Healing
Prolotherapy depends on your body’s ability to repair tissue after the inflammatory signal is sent. Smoking is one of the clearest threats to that process. Nicotine diminishes the production of growth factors and other molecules essential to wound healing. Animal studies have shown that nicotine exposure negatively impacts tendon healing after injury in both the shoulder and Achilles tendon. Smoking is also an established risk factor for tendon degeneration, meaning smokers may have more compromised tissue to begin with and less biological capacity to repair it.
Activity level after injections also plays a role. Too much stress on the treated area during the early healing phase can disrupt the repair process before new tissue has a chance to mature. Too little activity can limit blood flow to the area. Most practitioners recommend a middle ground of gentle movement, but specific guidance varies.
The Placebo Problem
Prolotherapy studies face a unique challenge: the control groups often receive saline or lidocaine injections, and those injections sometimes produce their own therapeutic effect. The physical act of needling tissue can itself stimulate some degree of healing response. In multiple trials, both the prolotherapy and control groups improved substantially, with the difference between them being small or statistically insignificant.
This doesn’t necessarily mean prolotherapy “doesn’t work” in the sense that patients don’t improve. Many do. The question is whether the improvement comes from the specific solution being injected or from the needle stimulus, the placebo effect, the natural course of healing over time, or the co-interventions (like exercise) that often accompany treatment. For someone who went through multiple sessions without meaningful relief, however, this distinction is academic. The treatment simply didn’t deliver.
When the Underlying Problem Is Wrong for Prolotherapy
Prolotherapy targets soft tissue injuries: partially torn ligaments, damaged tendons, worn cartilage surfaces. It’s not designed to address nerve compression, structural bone problems, autoimmune joint destruction, or pain that originates from sources other than connective tissue damage. A misdiagnosis or incomplete diagnosis can lead to prolotherapy being applied to a problem it was never going to fix. If the pain generator isn’t a ligament or tendon injury, stimulating inflammation in that area won’t address the actual cause.
Advanced joint degeneration also limits what prolotherapy can accomplish. If cartilage is severely worn or a ligament is completely torn rather than partially damaged, the remaining tissue may not have enough structural integrity to respond to a repair signal. The treatment is generally considered most appropriate for mild to moderate connective tissue injuries, not end-stage joint disease.